CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

“Hepatic fibrosis, the common response associated with chronic liver diseases, ultimately leads to cirrhosis, a major public health problem worldwide. We recently showed that activation of hepatic cannabinoid CB2 receptors limits progression of experimental liver fibrosis… In conclusion, our study shows that CB1 receptor antagonists hold promise for the treatment of liver fibrosis.”

http://www.ncbi.nlm.nih.gov/pubmed/16715087

Facebook Twitter Pinterest Stumbleupon Tumblr Posterous

One thought on “CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis.

Leave a Reply

Your email address will not be published. Required fields are marked *